142 related articles for article (PubMed ID: 19930738)
21. [Vaccines against human papillomavirus (HPV); between registration and implementation].
van Rossum TG; de Melker HE; Houweling H; Voordouw AC; Meijer CJ; Helmerhorst TJ; Kretzschmar M; Berkhof J; van der Noordaa J
Ned Tijdschr Geneeskd; 2008 Apr; 152(17):987-92. PubMed ID: 18549172
[TBL] [Abstract][Full Text] [Related]
22. Erythema multiforme following vaccination for human papillomavirus.
Katoulis AC; Liakou A; Bozi E; Theodorakis M; Alevizou A; Zafeiraki A; Mistidou M; Stavrianeas NG
Dermatology; 2010; 220(1):60-2. PubMed ID: 19887766
[TBL] [Abstract][Full Text] [Related]
23. [Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses].
Westra TA; Daemen T; Postma MJ; Wilschut JC
Ned Tijdschr Geneeskd; 2009; 153():A356. PubMed ID: 19930733
[TBL] [Abstract][Full Text] [Related]
24. Human papillomavirus vaccine safety in pediatric patients: an evaluation of the Vaccine Adverse Event Reporting System.
Borja-Hart NL; Benavides S; Christensen C
Ann Pharmacother; 2009 Feb; 43(2):356-9. PubMed ID: 19155346
[TBL] [Abstract][Full Text] [Related]
25. Papillomavirus vaccine types 16 and 18: new drug. Cervical cancer: just another vaccine.
Prescrire Int; 2008 Jun; 17(95):103-4. PubMed ID: 18623911
[TBL] [Abstract][Full Text] [Related]
26. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003.
McMahon AW; Iskander J; Haber P; Chang S; Woo EJ; Braun MM; Ball R
Pediatrics; 2005 Feb; 115(2):453-60. PubMed ID: 15687455
[TBL] [Abstract][Full Text] [Related]
27. Cervical cancer vaccination indications, efficacy, and side effects.
Bayas JM; Costas L; Muñoz A
Gynecol Oncol; 2008 Sep; 110(3 Suppl 2):S11-4. PubMed ID: 18586311
[TBL] [Abstract][Full Text] [Related]
28. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
29. [Impact of vaccination against oncogenic human papillomavirus on the incidence and mortality of cervical cancer in Germany].
Schneider A; Schwarz TF; Hammerschmidt T; Siebert U
Med Klin (Munich); 2007 Jul; 102(7):515-23. PubMed ID: 17634869
[TBL] [Abstract][Full Text] [Related]
30. Who should get the HPV vaccine?
Pichichero ME
J Fam Pract; 2007 Mar; 56(3):197-202. PubMed ID: 17343808
[No Abstract] [Full Text] [Related]
31. The association of adverse events with bivalent human papilloma virus vaccination: A nationwide register-based cohort study in Finland.
Skufca J; Ollgren J; Artama M; Ruokokoski E; Nohynek H; Palmu AA
Vaccine; 2018 Sep; 36(39):5926-5933. PubMed ID: 30115524
[TBL] [Abstract][Full Text] [Related]
32. Human papillomavirus vaccine recommendations and agreement with mandated human papillomavirus vaccination for 11-to-12-year-old girls: a statewide survey of Texas physicians.
Kahn JA; Cooper HP; Vadaparampil ST; Pence BC; Weinberg AD; LoCoco SJ; Rosenthal SL
Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2325-32. PubMed ID: 19661092
[TBL] [Abstract][Full Text] [Related]
33. Adverse effects of papillomavirus vaccines: pharmacovigilance data in 2008.
Prescrire Int; 2009 Aug; 18(102):163. PubMed ID: 19743577
[TBL] [Abstract][Full Text] [Related]
34. Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists.
; Collins Y; Einstein MH; Gostout BS; Herzog TJ; Massad LS; Rader JS; Wright J
Gynecol Oncol; 2006 Sep; 102(3):552-62. PubMed ID: 16979432
[TBL] [Abstract][Full Text] [Related]
35. Adverse events following immunization in Ontario's female school-based HPV program.
Harris T; Williams DM; Fediurek J; Scott T; Deeks SL
Vaccine; 2014 Feb; 32(9):1061-6. PubMed ID: 24440208
[TBL] [Abstract][Full Text] [Related]
36. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015.
Arana JE; Harrington T; Cano M; Lewis P; Mba-Jonas A; Rongxia L; Stewart B; Markowitz LE; Shimabukuro TT
Vaccine; 2018 Mar; 36(13):1781-1788. PubMed ID: 29477308
[TBL] [Abstract][Full Text] [Related]
37. Reports of Postural Orthostatic Tachycardia Syndrome After Human Papillomavirus Vaccination in the Vaccine Adverse Event Reporting System.
Arana J; Mba-Jonas A; Jankosky C; Lewis P; Moro PL; Shimabukuro TT; Cano M
J Adolesc Health; 2017 Nov; 61(5):577-582. PubMed ID: 29061232
[TBL] [Abstract][Full Text] [Related]
38. Human papillomavirus vaccine acceptability among young adult men.
Gerend MA; Barley J
Sex Transm Dis; 2009 Jan; 36(1):58-62. PubMed ID: 18830138
[TBL] [Abstract][Full Text] [Related]
39. Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain.
Gauthier A; Martín-Escudero V; Moore L; Ferko N; de Sanjosé S; Pérez-Escolano I; Catalá-López F; Ferrer E; Bosch FX
Eur J Public Health; 2008 Dec; 18(6):674-80. PubMed ID: 18641420
[TBL] [Abstract][Full Text] [Related]
40. Young adults and acceptance of the human papillomavirus vaccine.
Lenselink CH; Schmeink CE; Melchers WJ; Massuger LF; Hendriks JC; van Hamont D; Bekkers RL
Public Health; 2008 Dec; 122(12):1295-301. PubMed ID: 18619631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
